Maravai LifeSciences Announces Preliminary Unaudited 2024 Revenue

Core Viewpoint - Maravai LifeSciences Holdings, Inc. expects to report total revenue for 2024 near the mid-point of the previously announced guidance range of $255.0 million to$265.0 million, based on preliminary year-end results [1][4]. Financial Results Announcement - The company plans to announce its fourth quarter and full year 2024 financial and operating results after the market closes on February 25, 2025, and will host a conference call and webcast at 2:00 p.m. PT/5:00 p.m. ET on the same day [2]. Company Overview - Maravai is a leading life sciences company that provides critical products for the development of drug therapies, diagnostics, and novel vaccines, supporting research on human diseases. The company specializes in nucleic acid synthesis and biologics safety testing for biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies [5].